Epigallocatechin-3-gallate (EGCG) attenuates non-alcoholic fatty liver disease via modulating the interaction between gut microbiota and bile acids

The spectrum of non-alcoholic fatty liver disease (NAFLD) ranges from simple hepatic steatosis commonly associated with obesity, to non-alcoholic steatohepatitis, which can progress to fibrosis, cirrhosis and hepatocellular carcinoma. Recent reports have indicated the crucial role of gut microbiota...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Clin Biochem Nutr
Main Authors: Naito, Yuji, Ushiroda, Chihiro, Mizushima, Katsura, Inoue, Ryo, Yasukawa, Zenta, Abe, Aya, Takagi, Tomohisa
Formato: Artigo
Idioma:Inglês
Publicado: the Society for Free Radical Research Japan 2020
Assuntos:
Review
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7417793/
https://ncbi.nlm.nih.gov/pubmed/32801462
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3164/jcbn.20-39
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares